product summary
Loading...
company name :
DIMA Biotechnology
product type :
antibody
product name :
Anti-B7-H3 (enoblituzumab biosimilar) mAb
catalog :
BME100010
quantity :
50 μl, 100 μl
price :
80 USD, 160 USD
clonality :
monoclonal
host :
human
conjugate :
nonconjugated
clone name :
BME100010
reactivity :
human
application :
flow cytometry
more info or order :
DIMA Biotechnology product webpage
product information
Catalog Number :
BME100010
Product Name :
Anti-B7-H3 (enoblituzumab biosimilar) mAb
Product Type :
antibody
Host Species :
Humanized
Clonality :
Monoclonal
Conjugation :
Unconjugated
Antigen Modification :
no modification
Clone Name :
BME100010
Isotype :
IgG1
Light Chain :
kappa
Size :
50 μl, 100 μl
List Price :
80 USD, 160 USD
Product Description :
Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
SpeciesSummary :
Human
Immunogen :
B7-H3
Specificity :
ELISA, Flow Cyt
Purity :
Purified from cell culture supernatant by affinity chromatography
Buffer :
50% Glycerol; PBS, pH 7.4; 0.1% BSA
Preservative :
0.1% Procline 300
Packaging :
10ul/100ul
Uses :
Research use only
Application Summary :
Flow Cyt 1/100
Storage :
Store at -20°C (Avoid repeated freezing and thawing)
more info or order :
DIMA Biotechnology product webpage
company information
DIMA Biotechnology
Wuhan institute of Biotechnology B7
Biolake No.666 Gaoxin Road
Wuhan, Hubei
info@dimabio.com
https://www.dimabio.com
0118615307149771
headquarters: China
DIMA BIOTECH LTD (DIMABIO) focuses exclusively on the pre-clinical research market of Immune Oncology. Currently, we offer functional proteins and recombinant monoclonal antibodies. Our proprietary DimAb™ technology platform can directly clone IgG gene from immunized animal, which is a technology breakthrough in monoclonal antibody development.

All DIMABIOs protein products were manufactured by using mammalian cell expression system. To analyze the function of DIMABIOs proteins, we evaluated them by paired binding test between native ligand-receptor and or the binding capacity to the therapeutic antibodies. For DimAb™ recombinant monoclonal antibodies, we focus mainly on identifying clones with flow and blocking activity.